Atogepant Eases Migraine Aura Pain and Anxiety: New Insights

Research Summary

In a study published in The Journal of Headache and Pain, researchers investigated the potential of oral atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, to reduce pain and anxiety linked to migraine aura in mice. Using an innovative method to induce spreading depolarization (SD) in mice, which mimics migraine aura, the study found that SD significantly increased facial pain and anxiety-like behavior. Remarkably, atogepant administration before SD induction reduced these symptoms, particularly alleviating facial pain and anxiety. While atogepant didn't completely reverse the pain, it significantly improved overall symptoms, highlighting its promise for managing migraine-related pain and anxiety in humans.

Study Details

📄 Title: Oral atogepant mitigates spreading depolarization-induced pain and anxiety behavior in mice.

👥 Research Team: Kaya MZ et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Aug 21

🔗 Read Study

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.